 |
11 Diseases |  |
6 Trials |
|
6 Trials |  |
318 News |  |
| 1234» |
- | Plegridy (PEG-interferon ?-1a) / Biogen
Journal, Real-world evidence, Real-world: Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in a real-world setting: Final results from the Plegridy Observational Program. (Pubmed Central) - May 24, 2024
P=N/A
Peginterferon beta-1a is an effective therapy for managing relapsing multiple sclerosis. The identification of predictors of discontinuation can help inform strategies to enhance treatment persistence.
- | Mavenclad (cladribine) / EMD Serono
Enrollment closed: DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov) - May 1, 2024
P4, N=800, Active, not recruiting, Sponsor: The Cleveland Clinic
The identification of predictors of discontinuation can help inform strategies to enhance treatment persistence. Recruiting --> Active, not recruiting
- Plegridy (PEG-interferon ?-1a) / Biogen, Avonex (recombinant IFN-?-1a) / Biogen
Evaluating the Use and Efficacy of Avonex and Plegridy in Pediatric Patients (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_4474;
Recruiting --> Active, not recruiting Objective:Summarize the demographic/clinical characteristics and efficacy outcomes of individuals with pediatric-onset multiple sclerosis (POMS) who were treated with Avonex or PlegridyBackground:IM interferon beta-1a (Avonex
- | Plegridy (PEG-interferon ?-1a) / Biogen
Journal: Pregnancy outcomes in female multiple sclerosis patients exposed to intramuscular interferon beta-1a or peginterferon beta-1a reported in a German Patient Support Programme - results from the non-interventional post-authorization safety study PRIMA. (Pubmed Central) - Dec 18, 2023
P=N/A
These real-world data from a PSP corroborate European and Scandinavian registry data. NCT04655222, EUPAS38347.
- || Vumerity (diroximel fumarate) / Biogen
Enrollment change: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate (clinicaltrials.gov) - Oct 13, 2023
P=N/A, N=1178, Recruiting, Sponsor: Biogen
NCT04655222, EUPAS38347. N=825 --> 1178
- |||||| Betaseron (IFN-?-1b) / Bayer
New trial: INFORM: An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden (clinicaltrials.gov) - Sep 26, 2023
P=N/A, N=100, Not yet recruiting, Sponsor: Bayer
- | Mavenclad (cladribine) / EMD Serono
Trial completion date, Trial primary completion date: DELIVER-MS: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (clinicaltrials.gov) - Aug 16, 2023
P4, N=800, Recruiting, Sponsor: The Cleveland Clinic
N=825 --> 1178 Trial completion date: Sep 2026 --> Sep 2030 | Trial primary completion date: Dec 2025 --> Apr 2030
- | Plegridy (PEG-interferon ?-1a) / Biogen
Journal: Interferon ?-1a ring prophylaxis to reduce household transmission of SARS-CoV-2: a cluster randomised clinical trial. (Pubmed Central) - Aug 4, 2023
P3
Biogen PTY Ltd. Supply of interferon as 'Plegridy (peginterferon beta-1a).' The study was substantially funded by BHP Holdings Pty Ltd.
- | Plegridy (PEG-interferon ?-1a) / Biogen
Journal: Impact of interferon beta exposure on birth outcome and child development - Results from the post-authorisation safety study PRIMA. (Pubmed Central) - Jul 2, 2023
P=N/A
Study results confirmed former reports indicating that exposure to interferon beta therapies during pregnancy or lactation had no adverse effects on intrauterine growth and child development over the study period, which covered the first 4 years of life. These real-world data obtained within the scope of a patient support program for peginterferon beta-1a or IM interferon beta-1a corroborate German and Scandinavian registry data and support the label update of all interferon beta therapies.
- | Plegridy (PEG-interferon ?-1a) / Biogen, Avonex (recombinant IFN-?-1a) / Biogen
Journal: Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-?-1a Compared to Non-PEGylated IFN-?-1a. (Pubmed Central) - Mar 24, 2023
balanced correlations of expression among these genes and proteins, with positive correlations between Th1 and Th2 families, quelling the "cytokine storm" of untreated MS. Both IFNs induced long-term, potentially beneficial, molecular effects on immune and possibly neuroprotective pathways in MS.
- | Plegridy (PEG-interferon ?-1a) / Biogen, teriflunomide / Generic mfg.
Journal: Recurrent encephalopathy associated with pegylated beta-interferon treatment. (Pubmed Central) - Mar 7, 2023
Both IFNs induced long-term, potentially beneficial, molecular effects on immune and possibly neuroprotective pathways in MS. These episodes occurred about 3
- |||||| Vumerity (diroximel fumarate) / Biogen
New trial: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate (clinicaltrials.gov) - Jan 18, 2023
P=N/A, N=825, Recruiting, Sponsor: Biogen
- ||| Plegridy (PEG-interferon ?-1a) / Biogen
Trial termination: Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants (clinicaltrials.gov) - Dec 2, 2022
P3, N=11, Terminated, Sponsor: Biogen
These episodes occurred about 3 Completed --> Terminated; Decision to stop the trial was based on long-term difficulties in fulfilling our enrolment commitments and changes in paediatric MS landscape which no longer support placebo-controlled trials.Decision to stop study was not based on safety concerns.
- Plegridy (PEG-interferon β-1a) / Biogen
Interferon beta exposure during pregnancy and breastfeeding: Impact on birth outcome and child development – Results from the post-authorisation safety study PRIMA (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_599;
Data support and complement the label update of all interferon beta therapies and here especially PegIFNβ-1a and IM IFNβ-1a. Study Support: Biogen.
- || Plegridy (PEG-interferon β-1a) / Biogen
P1 data, PK/PD data, Clinical Trial,Phase I, Journal: Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study. (Pubmed Central) - Sep 14, 2022
No clinically meaningful differences were identified between Black and White participants related to peginterferon β-1a administration, supporting the approved dose of 125 μg/mL peginterferon β-1a. Future clinical studies should include sufficiently diverse populations to ensure accurate assessments of treatment response.
- || Plegridy (PEG-interferon ?-1a) / Biogen
Trial completion: Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants (clinicaltrials.gov) - Aug 11, 2022
P3, N=11, Completed, Sponsor: Biogen
Future clinical studies should include sufficiently diverse populations to ensure accurate assessments of treatment response. Active, not recruiting --> Completed
- | Mavenclad (cladribine) / EMD Serono
Trial completion date, Trial primary completion date: TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov) - Jul 19, 2022
P=N/A, N=900, Recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
- Plegridy (PEG-interferon β-1a) / Biogen, Avonex (recombinant IFN-β-1a) / Biogen
Working productivity in patients CIS/ CDMS treated with Avonex® or Plegridy®: real-word evidence from the Czech republic (Virtual) - Jul 18, 2022 - Abstract #EAN2022EAN_1798;
- ||| Plegridy (PEG-interferon β-1a) / Biogen
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Biogen Multiple Sclerosis Pregnancy Exposure Registry (clinicaltrials.gov) - Jun 22, 2022
P=N/A, N=408, Completed, Sponsor: Biogen
Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025 Recruiting --> Completed | N=1125 --> 408 | Trial completion date: Dec 2028 --> Feb 2022 | Trial primary completion date: May 2028 --> Feb 2022
- | Plegridy (PEG-interferon β-1a) / Biogen
Journal: Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients. (Pubmed Central) - May 18, 2022
Minimal concentrations of peginterferon beta-1a were detected in the breast milk samples. These findings may be useful for clinicians considering postpartum MS treatment options.
- Plegridy (PEG-interferon β-1a) / Biogen
Patient-Reported Outcomes for Patients Treated with Peginterferon Beta-1a: Plegridy Observational Program Interim Analysis (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) - May 9, 2022 - Abstract #CMSC2022CMSC_140;
These results indicate that peginterferon beta-1a can provide improvements in outcomes important for both ND and NND patients. Support: Biogen
- ||||| Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants (clinicaltrials.gov) - Apr 5, 2022
P3, N=11, Active, not recruiting, Sponsor: Biogen
Support: Biogen Recruiting --> Active, not recruiting | N=260 --> 11 | Trial completion date: Nov 2021 --> Jul 2022 | Trial primary completion date: Nov 2021 --> Jul 2022
- Plegridy (PEG-interferon β-1a) / Biogen
Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program (POP) Interim Analysis (Poster Hall) - Mar 6, 2022 - Abstract #AAN2022AAN_2535;
Key differences were observed in their safety profiles, and AA patients were more likely than NAA patients to discontinue peginterferon beta-1a because of AEs. These results help characterize the experience of AA patients in a real-world setting and may inform health care providers on safety considerations in this population.
- | Plegridy (PEG-interferon β-1a) / Biogen
Journal, Real-world evidence: Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program. (Pubmed Central) - Feb 16, 2022
Safety data of patients enrolled in POP are consistent with the established clinical safety profile of peginterferon beta-1a. In addition, the low ARR and high proportion of patients achieving clinical NEDA at 4 years across all subgroups indicates the effectiveness of peginterferon beta-1a in treating RMS in real-world clinical settings.
- || Plegridy (PEG-interferon β-1a) / Biogen
Clinical data, Journal: Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN. (Pubmed Central) - Feb 16, 2022
P3
These results indicate that newly diagnosed and non-newly diagnosed patients treated continuously with peginterferon beta-1a Q2W experienced better disease control over time than those who received delayed treatment. Patients with NEDA or evidence of less radiological disease activity in the first 2 years of treatment had better longer-term clinical outcomes than those with evidence of greater disease activity.
- ||| Plegridy (PEG-interferon β-1a) / Biogen
Trial completion, Real-world evidence, Real-world effectiveness, Real-world: Plegridy Observational Program (clinicaltrials.gov) - Feb 11, 2022
P=N/A, N=1208, Completed, Sponsor: Biogen
Patients with NEDA or evidence of less radiological disease activity in the first 2 years of treatment had better longer-term clinical outcomes than those with evidence of greater disease activity. Active, not recruiting --> Completed
- | Plegridy (PEG-interferon β-1a) / Biogen
.@biogen Your drug, Plegridy, almost killed me. How do I claim compensation? (Twitter) - Jan 13, 2022
- || Clinical, Retrospective data, Journal: Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data. (Pubmed Central) - Nov 25, 2021
We have showed the feasibility of merging routinely-collected healthcare data to a clinical registry for future MS research, and have confirmed interferon beta formulations play an important role in the management of MS, with positive clinical outcomes. Differences between interferon beta formulations are mostly driven by adherence and healthcare resource utilization.
- ||| Plegridy (PEG-interferon β-1a) / Biogen
Trial completion, Enrollment change: Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program (clinicaltrials.gov) - Nov 2, 2021
P=N/A, N=470, Completed, Sponsor: Biogen
Differences between interferon beta formulations are mostly driven by adherence and healthcare resource utilization. Recruiting --> Completed | N=8544 --> 470
- || Plegridy (PEG-interferon β-1a) / Biogen
Clinical, Journal: Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring. (Pubmed Central) - Oct 27, 2021
P3
sNfL was higher and more variable in patients with evidence of active MS. These data support sNfL as a prognostic and disease-monitoring biomarker for RRMS.
- Plegridy (PEG-interferon β-1a) / Biogen
[VIRTUAL] Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis () - Oct 8, 2021 - Abstract #CMSC2021CMSC_638;
Key differences were observed in their safety profiles, and AA patients were more likely to discontinue peginterferon beta-1a due to AEs than NAA patients. These results help to characterize the experience of AA patients in a real-world setting and may inform health care providers on safety considerations in this population.
- Plegridy (PEG-interferon β-1a) / Biogen
[VIRTUAL] Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a () - Oct 8, 2021 - Abstract #CMSC2021CMSC_486;
Lower levels of employment and education were both associated with greater burden of disease. Additional studies with longer observation times may help identify potentially modifiable risk factors.
- glatiramer acetate / Generic mfg.
[VIRTUAL] Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans () - Oct 8, 2021 - Abstract #CMSC2021CMSC_454;
This finding cannot be explained solely by the dosing schedule and may relate to the higher incidence of flu-like symptoms with IFNs than with GA. These results highlight an increase in PEG adherence that may reflect the increase in education and training on setting expectations for potential AEs.
- [VIRTUAL] COVID-19 Vaccine Response in People with MS Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy (GATLIN A3/A4) - Oct 8, 2021 - Abstract #CMSC2021CMSC_117;
This prospective open-label observational study is recruiting 120 participants (natalizumab [NTZ] n=30, ocrelizumab [OCR] n=30, fumarate [FUM] (dimethyl fumarate [DMF] or diroximel fumarate [DRF] n=30), and interferon [IFN, any IFN and peginterferon beta-1a] n=30) ages 18 65 years inclusive, with a diagnosis of relapsing MS who are stable on their current DMT for >6 months... This study will provide healthcare practitioners with additional quantitative data on the humoral immune response to mRNA-1273 COVID-19 vaccination in MS patients treated by various DMTs.
- [VIRTUAL] Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: merging the real-life to routinely collected healthcare data (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2401;
We have showed the feasibility of merging routinely-collected healthcare data to a clinical registry for future MS research, and have confirmed interferon beta formulations play an important role in the management of MS, with positive clinical outcomes. Differences between interferon beta formulations are mostly driven by adherence and healthcare resource utilization.
- Plegridy (PEG-interferon β-1a) / Biogen
[VIRTUAL] Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis: Plegridy Observational Program interim results (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2396;
ND patients were more likely to experience FLS than NND patients, whereas the opposite was true for ISRs, indicating a need for targeted mitigation and management strategies. The low ARR and high proportion of relapse-free patients at 4 years in both the ND and NND subgroups supports the effectiveness of peginterferon beta-1a in the treatment of RMS.
- Plegridy (PEG-interferon β-1a) / Biogen
[VIRTUAL] Comparison of pharmacokinetic profiles and safety outcomes with peginterferon beta-1a administration in Black/African American and White participants (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2233;
Therefore, no dose adjustment should be needed for different racial groups. This study is the first to compare PK profiles of an interferon or MS disease-modifying therapy between racial groups.
- | Plegridy (PEG-interferon ?-1a) / Biogen
Trial completion, Trial completion date: ConCorD-19: The Containing Coronavirus Disease 19 (COVID-19) Trial (clinicaltrials.gov) - Sep 9, 2021
P3, N=1173, Completed, Sponsor: Pontificia Universidad Catolica de Chile
This study is the first to compare PK profiles of an interferon or MS disease-modifying therapy between racial groups. Recruiting --> Completed | Trial completion date: Dec 2021 --> Jun 2021
- Plegridy (PEG-interferon β-1a) / Biogen
[VIRTUAL] Comparison of pharmacokinetic profiles and safety outcomes with peginterferon beta-1a administration in Black/African American and White participants (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_887;
Therefore, no dose adjustment should be needed for different racial groups. This study is the first to compare PK profiles of an interferon or MS disease-modifying therapy between racial groups.
- [VIRTUAL] Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: merging the real-life to routinely collected healthcare data (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_782;
We have showed the feasibility of merging routinely-collected healthcare data to a clinical registry for future MS research, and have confirmed interferon beta formulations play an important role in the management of MS, with positive clinical outcomes. Differences between interferon beta formulations are mostly driven by adherence and healthcare resource utilization.
- Plegridy (PEG-interferon β-1a) / Biogen
[VIRTUAL] Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis: Plegridy Observational Program interim results (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_777;
ND patients were more likely to experience FLS than NND patients, whereas the opposite was true for ISRs, indicating a need for targeted mitigation and management strategies. The low ARR and high proportion of relapse-free patients at 4 years in both the ND and NND subgroups supports the effectiveness of peginterferon beta-1a in the treatment of RMS.
- ||| Plegridy (PEG-interferon ?-1a) / Biogen
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jul 20, 2021
P3, N=142, Recruiting, Sponsor: Biogen
The low ARR and high proportion of relapse-free patients at 4 years in both the ND and NND subgroups supports the effectiveness of peginterferon beta-1a in the treatment of RMS. Trial completion date: Mar 2023 --> Nov 2029 | Trial primary completion date: Mar 2023 --> Nov 2029
- || Plegridy (PEG-interferon β-1a) / Biogen
It’s a good tool although missing Plegridy? 🧐 (Twitter) - Jul 13, 2021
- || Plegridy (PEG-interferon β-1a) / Biogen
Clinical, Journal, Real-world evidence: Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. (Pubmed Central) - Jul 9, 2021
Also, all other measured secondary outcomes did not differ between study cohorts. These real-world data may help support decision-making in the treatment of patients with RRMS.
- ||| Plegridy (PEG-interferon β-1a) / Biogen
Enrollment open: Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program (clinicaltrials.gov) - Jun 18, 2021
P=N/A, N=8544, Recruiting, Sponsor: Biogen
These real-world data may help support decision-making in the treatment of patients with RRMS. Not yet recruiting --> Recruiting
- | Fumaderm (dimethyl fumarate) / Biogen
Journal: The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden. (Pubmed Central) - Jun 10, 2021
Disease progression rates from previous MS Markov cohort models were applied to interferon beta-1a, peginterferon beta-1a, dimethyl fumarate, and natalizumab using a public economic framework...The lifetime social insurance transfer costs were highest in non-treated patients, and lower social insurance costs were demonstrated with DMTs. These findings suggest that focusing cost-effectiveness analysis only on health costs will likely underestimate the value of DMTs.
- || Plegridy (PEG-interferon β-1a) / Biogen
Clinical, Observational data, Journal: Subcutaneous Interferon Beta Therapy in Multiple Sclerosis Patients - Characterization of Injection Site Reactions and Flu-Like Symptoms in a Daily Practice Setting - Results from the Non-Interventional Study PERFECT. (Pubmed Central) - Jun 4, 2021
Although ISR were experienced by the majority of patients, they rarely resulted in treatment interruption. In this real-world setting, ISR and FLS management was in line with published expert recommendations.
- | Mavenclad (cladribine) / EMD Serono
Trial completion date, Trial primary completion date: TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov) - Jun 1, 2021
P=N/A, N=900, Recruiting, Sponsor: Johns Hopkins University
In this real-world setting, ISR and FLS management was in line with published expert recommendations. Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
- | Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: Drugs for multiple sclerosis. (Pubmed Central) - May 25, 2021
Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024 No abstract available
- || Plegridy (PEG-interferon β-1a) / Biogen
Clinical, Journal, Real-world evidence: Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management. (Pubmed Central) - May 11, 2021
No abstract available Patient education and counseling play a key role in promoting adherence to treatment especially in the first months also in patients switching from nonpegylated IFNs to peginterferon beta-1a.